Skip to content
Provider review · Ranked #45

EdgeRx review

A men's-only protocol shop with flat, disclosed GLP-1 pricing, a named Chief Medical Advisor, and a named 503A compounding pharmacy — rare transparency for this tier of the ranking.

At a glance

Semaglutide
$229/mo
Tirzepatide
$299/mo
State access
Check eligibility
Brand-name access
Not established in this review
Visit EdgeRx ↗

We may earn a referral commission through this link, at no extra cost to you. How we are funded.

Each price keeps its conditions. See What does EdgeRx cost? for the complete published terms.

In this review

Is EdgeRx legit?

Only what EdgeRx publishes and what we could check ourselves. See the methodology.

Certification
EdgeRx publishes a LegitScript certification on its own pages.
Where it ships

46 states (excludes Arkansas, Indiana, Minnesota, South Carolina), as published on the site. When checking alternatives to EdgeRx, ask whether the exact treatment can be prescribed and dispensed in your state before you compare plan prices.

Published price
EdgeRx publishes a figure for semaglutide and tirzepatide — the qualifiers are in "What does EdgeRx cost?" below.
What it sells
Confirm the exact medication and route before starting intake.
Licensing & trust
88/100 on the scored dimension of that name — one of the six in our published methodology.

A month-to-month rate is published in the dated information reviewed. Confirm treatment-specific state access and the full purchase terms before choosing a provider.

What does EdgeRx cost?

Each figure keeps its billing conditions. Our GLP-1 cost guide explains how to compare medication charges, program fees and prepaid plans. Our ranked semaglutide providers show how other programs bill for the same medication.

Semaglutide

$229/mo injectable

That is a flat month-to-month rate: $229 a month, with no plan term attached to the figure. Use the EdgeRx vs CoreAge Rx comparison to check which costs apply to the same medication and billing interval. To see how other programs publish these terms, read our MadeMed review and our yourEra review; we may earn a commission from both.

Median semaglutide figure across this site: $190 a month, of 164 providers with a published month-to-month price and a check date. EdgeRx's $229 a month sits $39 above it.

Tirzepatide

$299/mo injectable

That is a flat month-to-month rate: $299 a month, with no plan term attached to the figure.

Median tirzepatide figure across this site: $259 a month, of 165 providers with a published month-to-month price and a check date. EdgeRx's $299 a month sits $40 above it.

Prices can change. Confirm the complete charge and renewal terms before ordering.

Desk Score breakdown

Each of the six scored dimensions. See the methodology.

Price transparency82/100
State access80/100
Molecule range78/100
Onboarding speed82/100
Support responsiveness78/100
Licensing & trust88/100

What we like

  • Both molecules disclosed up front — semaglutide $229/mo, tirzepatide $299/mo, both once-weekly injectable with free shipping
  • Named compounding pharmacy — Strive Pharmacy, 503A, operating since 2018
  • Named Chief Medical Advisor, Dr. John Starke, MD (ABEM board-certified)
  • LegitScript certified

Where points come off

  • Men-only — not built for or marketed to women or other readers
  • The named Chief Medical Advisor does not personally prescribe; the prescribing pool is unnamed licensed physicians
  • Third-party lab testing claimed but no specific lab named
  • Excludes Arkansas, Indiana, Minnesota, and South Carolina

The bottom line — B−

Best for: Men who want a straightforward, disclosed weekly-injectable price on either molecule and value knowing the pharmacy by name.

EdgeRx ranks #45 of 545 providers scored; our CoreAge Rx review covers the provider ranked #1.

Related reviews

Everyone else here (24)

Pricing and verification reflect EdgeRx's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on EdgeRx's site. Not medical advice; see our disclosure.

← Back to the ranking